203 related articles for article (PubMed ID: 30156152)
1. Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications.
Yamagishi SI; Matsui T
Curr Pharm Des; 2018; 24(24):2802-2809. PubMed ID: 30156152
[TBL] [Abstract][Full Text] [Related]
2. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
3. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
4. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
5. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
6. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
7. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
Yamagishi SI
Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
[TBL] [Abstract][Full Text] [Related]
8. Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.
Higashimoto Y; Matsui T; Nishino Y; Taira J; Inoue H; Takeuchi M; Yamagishi S
Microvasc Res; 2013 Nov; 90():64-70. PubMed ID: 24012635
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
10. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
11. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
12. Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE.
Matsui T; Oda E; Higashimoto Y; Yamagishi S
Cardiovasc Diabetol; 2015 Jan; 14():1. PubMed ID: 25582325
[TBL] [Abstract][Full Text] [Related]
13. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
Yamagishi SI; Sotokawauchi A; Matsui T
Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
[TBL] [Abstract][Full Text] [Related]
14. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
Yamagishi S
Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
Yamagishi S; Fukami K; Matsui T
Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
[TBL] [Abstract][Full Text] [Related]
16. [Bone metabolism and cardiovascular function update. Impairment of osteo-vascular interaction by glyco-oxidative stress].
Yamagishi SI
Clin Calcium; 2014 Jul; 24(7):85-91. PubMed ID: 24976060
[TBL] [Abstract][Full Text] [Related]
17. DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis.
Ojima A; Matsui T; Nakamura N; Higashimoto Y; Ueda S; Fukami K; Okuda S; Yamagishi S
Horm Metab Res; 2015 Apr; 47(4):253-8. PubMed ID: 25105541
[TBL] [Abstract][Full Text] [Related]
18. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
19. Role of Ligands of Receptor for Advanced Glycation End Products (RAGE) in Peripheral Artery Disease.
Yamagishi SI; Matsui T
Rejuvenation Res; 2018 Oct; 21(5):456-463. PubMed ID: 29644926
[TBL] [Abstract][Full Text] [Related]
20. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
